KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Equity Average (2016 - 2026)

Edwards Lifesciences has reported Equity Average over the past 16 years, most recently at $10.3 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 4.41% year-over-year to $10.3 billion; the TTM value through Dec 2025 reached $10.3 billion, up 4.41%, while the annual FY2025 figure was $10.2 billion, 21.56% up from the prior year.
  • Equity Average for Q4 2025 was $10.3 billion at Edwards Lifesciences, down from $10.4 billion in the prior quarter.
  • Over five years, Equity Average peaked at $10.4 billion in Q3 2025 and troughed at $4.6 billion in Q1 2021.
  • A 5-year average of $7.2 billion and a median of $6.4 billion in 2023 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: rose 1.61% in 2023 and later surged 46.32% in 2024.
  • Year by year, Equity Average stood at $5.7 billion in 2021, then rose by 5.69% to $6.0 billion in 2022, then rose by 11.83% to $6.7 billion in 2023, then surged by 46.32% to $9.8 billion in 2024, then grew by 4.41% to $10.3 billion in 2025.
  • Business Quant data shows Equity Average for EW at $10.3 billion in Q4 2025, $10.4 billion in Q3 2025, and $10.4 billion in Q2 2025.